Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis

Huang, Yong; Fan, Shwu; Espíndola, Milena S.; Vij, Rekha; Oldham, Justin M.; Huffnagle, Gary B.; Erb-Downward, John R.; Flaherty, Kevin R.; Moore, Bethany B.; White, Eric S.; Zhou, Tong; Lǐ, Jiànróng; Lussier, Yves A.; Han, MeiLan K.; Kaminski, Naftali; Garcia, Joe G.N.; Hogaboam, Cory M.; Martínez, Fernando J.; Noth, Imre

doi:10.1164/rccm.201607-1525oc

Cited by 120 publications

(115 citation statements)

References 57 publications

(24 reference statements)

Supporting

Mentioning

109

Contrasting

Order By: Relevance

“…An imbalance in the host-microbial relationship is thought to contribute to inflammation and immunity in the IPF lung [24]. It is well known that the pulmonary collectins, surfactant proteins A and D, have an important role in the alveolar spaces and are useful biomarkers in IPF [25].…”

Section: Discussionmentioning

confidence: 99%

Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis

et al. 2018

View full text Add to dashboard Cite

Background: Idiopathic pulmonary fibrosis (IPF) is the most frequent and severe form of idiopathic interstitial pneumonias. Although IPF has not been thought to be associated with bacterial communities, recent papers reported the possible role of microbiome composition in IPF. The roles of microbiomes in respiratory functions and as clinical biomarkers for IPF remain unknown. In this study, we aim to identify the relationship between the microbial environment in the lung and clinical findings. Methods: Thirty-four subjects diagnosed with IPF were included in this analysis. The 16S rDNA was purified from bronchoalveolar lavage fluid obtained at the time of diagnosis and analyzed using next-generation sequencing techniques to characterize the bacterial communities. Furthermore, microbiomes from mice with bleomycininduced lung fibrosis were analyzed.

show abstract

Section: Discussionmentioning

confidence: 99%

Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In particular, up-and downregulation of immune-response-relevant pathways was associated with changes in the abundance of specific microbial operational taxonomic units, which had an impact on disease progression. Furthermore, the authors demonstrated an even more direct contribution of the host-microbiome interaction to the pathogenesis of the disease by influencing immune-mediated fibroblast responsiveness and the composition of circulating leukocytes [30].…”

Section: Ipf and Host-microbiota Interactions And Potential Effects mentioning

confidence: 99%

“…Other authors have recently tried to take a step forward in the understanding of the pathogenesis of IPF by assessing the interaction between the host and lung microbiota [29,30]. MOLYNEAUX et al [25] performed a longitudinal evaluation of host gene expression in peripheral blood cells from 60 IPF patients and 20 controls, from their prior contribution, and explored the potential association with BAL microbiota collected at baseline [29].…”

Section: Ipf and Host-microbiota Interactions And Potential Effects mentioning

confidence: 99%

“…In this preliminary study, the authors demonstrated that in IPF patients, when compared to controls, there were changes in the peripheral blood expression profile associated with the presence of an altered or more abundant microbiome. HUANG et al [30], once again using the data from the COMET-IPF study, showed that host defence, as assessed by immune pathway gene expression, could be modulated by variations in the lower airway microbiome. In particular, up-and downregulation of immune-response-relevant pathways was associated with changes in the abundance of specific microbial operational taxonomic units, which had an impact on disease progression.…”

Section: Ipf and Host-microbiota Interactions And Potential Effects mentioning

confidence: 99%

See 1 more Smart Citation

Long-term macrolides in diffuse interstitial lung diseases

Faverio¹,

Bini²,

Vaghi³

et al. 2017

Eur Respir Rev

View full text Add to dashboard Cite

In the present review we provide currently available evidence for the use of macrolides in the treatment of diffuse interstitial lung diseases (ILDs). Up to now, research on macrolides has mainly focused on three areas. First, macrolides have shown some promising results in cellular models and case reports as antifibrotic agents, by promoting autophagy and clearance of intracellular protein aggregates and acting as regulators of surfactant homeostasis. Secondly, macrolides have an immunomodulatory effect, which has been applied in some organising pneumonia cases. In particular, macrolides have been tested in association with systemic corticosteroids as steroid-sparing agents and alone as either first-line agents in mild cases or second-line agents where steroids were poorly tolerated or had failed. Thirdly, a recent area of research concerns the possible role of macrolides as modulators of lung microbiota and the host-microbiota interaction. This function has been particularly studied in idiopathic pulmonary fibrosis patients, in whom changes in microbiota have been proved to be associated with disease progression. However, the lack of high-quality studies makes the application of macrolide therapy in ILDs a field in which research should be conducted on a large scale.

show abstract

“…A diagnostic predictor for UIP based on transbronchial biopsy tissue sample gene expression using RNA-sequencing is under development (41). Two recent studies have linked circulating gene expression with abnormalities in the lung microbial community and clinical outcomes (42,43).…”

mentioning

confidence: 99%